LONDON - Silence Therapeutics plc, NASDAQ:SLN, revealed positive findings from the ongoing phase 2 study of its drug candidate zerlasiran, which is being developed to reduce lipoprotein(a) levels, a genetic risk factor for cardiovascular disease. The study, named ALPACAR-360, involves 178 subjects with high lipoprotein(a) levels and at risk of atherosclerotic cardiovascular disease events.
Zerlasiran, which is administered subcutaneously, showed a significant reduction in lipoprotein(a) levels at 36 weeks compared to a placebo, which was the study's primary endpoint. Patients experienced a median reduction in lipoprotein(a) of 90% or greater at both dosing schedules. The study has not raised any new safety concerns to date.
The 60-week study will continue to assess secondary endpoints, such as changes in lipoprotein(a) levels at 48 and 60 weeks, as well as potential effects on other lipids and lipoproteins. Silence Therapeutics anticipates reporting topline data from the 48-week mark in the second quarter of this year.
Steven Romano, MD, Head of Research and Development at Silence, expressed optimism about the phase 2 data aligning with phase 1 results, indicating a competitive profile for zerlasiran in treating patients with high lipoprotein(a).
This announcement is based on a press release statement from Silence Therapeutics plc. The company is focused on developing a new generation of medicines using RNA interference to silence disease-related genes. Its proprietary mRNAi GOLD™ platform targets the liver, aiming to address diseases with significant unmet medical needs. Silence Therapeutics maintains research and development collaborations with AstraZeneca (NASDAQ:AZN) and Hansoh Pharma, among others.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.